Compare DoorDash Inc (DASH) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs Danaher Corporation — how do they compare? DoorDash Inc trades at $211.16 (market cap $90.93B), while Danaher Corporation trades at $207.26 (market cap $147.18B). The key difference: Danaher Corporation is the larger of the two by market cap, and Danaher Corporation pays a 0.76% dividend while DoorDash Inc pays none. Which is the better fit depends on your goals.
| DASH | DHR | |
|---|---|---|
Market Cap | $90.93B | $147.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $281.74 | $242.05 |
52-Week Low | $146.60 | $161.91 |
Enterprise Value | $88.89B | $169.39B |
Dividend Yield | — | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $216.26, up 1.41% with strong technical momentum above key support levels. The company demonstrates robust revenue growth, with Q2 2026 revenue up 36% YoY to $4.45B, though earnings missed estimates due to higher R&D costs. Analyst sentiment remains overwhelmingly positive with 75.68% buy ratings and a $247.41 consensus price target, representing 14.4% upside potential from current levels.
DoorDash's expansion into grocery, retail, and international markets supports growth, but elevated valuation multiples (P/E 113.23) and intense competition present risks. The stock's technical strength and fundamental growth trajectory suggest continued upside, though investors should monitor execution on profitability targets and competitive pressures in the delivery space.
Danaher (DHR) trades at $204.76, up 2.37% today, near its pivot point of $203 with bullish technical signals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $1.92 EPS. Revenue for 2025 was $24.57B with a net income margin of 15.95%, though margins have trended down from 22.9% in 2022. Recent news includes the Masimo acquisition approval and a $172.5 million settlement over pandemic-era disclosures (Reuters, 2026-04-23).
Outlook is positive with strong analyst support (69% buy ratings) and a consensus price target of $202.33, slightly below current price. Risks include margin compression, high valuation (P/E 36.5), and integration challenges from acquisitions. Cash flow improved to $2.54B net in 2025 after a dip in 2023-2024, supporting dividend payments and growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
